Prevalence of hepatitis C among injection drug users in England and Wales: Is harm reduction working?
Prevalence of hepatitis C among injection drug users in England and Wales: Is harm reduction working?
复制标题
DOI：
10.2105/ajph.91.1.38
复制
发表时间：
2001-01-01
影响因子：
12.7
通讯作者：
Gill, ON
中科院分区：
文献类型：
--
作者：
Hope, VD;Judd, A;Gill, ON
目标.本研究旨在确定英格兰和威尔士注射吸毒者中丙型肝炎抗体（抗-HCV）和B肝炎抗体（抗-HBc）的患病率。方法：通过自愿横断面调查收集了口腔液样本和行为信息;通过药物机构招募了2203名注射者，并在社区招募了758名注射者。抗-HCV、抗-HBc和HIV抗体的患病率分别为30%、21%和0.9%。抗-HCV流行率显着更大的那些与较长的注射生涯，那些在老年组，那些居住在伦敦，那些在药物机构招募，那些抗-HBc阳性，和那些与以前的自愿艾滋病毒检测。英格兰和威尔士存在全面的减少伤害计划，注射者中的抗丙型肝炎病毒流行率低于其他工业化国家的流行率。
Objectives. This study sought to establish the prevalence of hepatitis C antibodies (anti-HCV) and hepatitis B antibodies (anti-HBc) among injection drug users in England and Wales.Methods.:A voluntary cross-sectional survey collected oral fluid samples and behavioral information; 2203 injectors were recruited through drug agencies, and 758 were recruited in the community.Results. Prevalence was 30% for anti-HCV, 21% for anli-HBc, and 0.9% for HIV antibodies. Anti-HCV prevalence rates were significantly greater among those with longer injecting careers, those in older age groups, those residing in London, those recruited in drug agencies, those positive for anti-HBc, and those with a previous voluntary HIV test.Conclusions. Anti-HCV prevalence rates among injectors in England and Wales, where comprehensive harm reduction programs exist, are lower than rates in other industrialized countries.